Please enable JavaScript to continue using this application.

Compare $RNTX vs $RNXT | Chartloom

Compare

$RNTX vs $RNXT

Rein Therapeutics Inc · RenovoRx Inc

RNTX

Rein Therapeutics Inc

RNXT

RenovoRx Inc

Compare $RNTX vs $RNXT

Comparing Rein Therapeutics Inc and RenovoRx Inc

RNTXRein Therapeutics Inc

RNXTRenovoRx Inc

RNTXRein Therapeutics Inc

Market cap

$68M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-36.5%

52W performance

-42.9%

FCF yield

-27.7%

RNXTRenovoRx Inc

Market cap

$58M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

8.70x

Rev growth (TTM)

198.5%

YTD performance

53.3%

52W performance

5.8%

FCF yield

-20.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RNTX

RNXT

Detailed metrics comparison

RNTX

Rein Therapeutics Inc

RNXT

RenovoRx Inc

Market Cap

RNTX$68M

RNXT$58M

Enterprise Value

RNTX$59M

RNXT$48M

Price

RNTX$0.79

RNXT$1.28

P/E Ratio

RNTXN/A

RNXTN/A

P/S Ratio

RNTX0.00x

RNXT29.18x

EV/Sales

RNTX0.00x

RNXT24.39x

EV/EBITDA

RNTX0.00x

RNXT0.00x

P/B Ratio

RNTX1.25x

RNXT7.94x

P/FCF Ratio

RNTXN/A

RNXTN/A

EV/FCF

RNTX-3.15x

RNXT-4.04x

PEG Ratio

RNTXN/A

RNXTN/A

Forward P/E (NTM)

RNTXN/A

RNXTN/A

Forward P/S (NTM)

RNTXN/A

RNXT8.70x

Revenue (TTM)

RNTX$0

RNXT$2M

Revenue Growth (YoY)

RNTXN/A

RNXT198.5%

Forward Rev Growth

RNTX113.7%

RNXT195.2%

Gross Margin (TTM)

RNTX0.0%

RNXT84.4%

Operating Margin (TTM)

RNTX0.0%

RNXT0.0%

EBITDA Margin (TTM)

RNTX0.0%

RNXT-684.9%

Net Margin (TTM)

RNTX0.0%

RNXT-621.7%

FCF Margin (TTM)

RNTXN/A

RNXT-604.1%

Net Income (TTM)

RNTX$-50M

RNXT$-12M

FCF (TTM)

RNTX$-19M

RNXT$-12M

EPS (TTM)

RNTX-$0.74

RNXT-$0.26

ROE (TTM)

RNTX-15323.0%

RNXT-14563.0%

ROA (TTM)

RNTX-11700.0%

RNXT-10984.0%

ROIC (TTM)

RNTX-14763.0%

RNXT-14563.0%

Cash

RNTX$9M

RNXT$9M

Debt

RNTX$0

RNXT$0

Net Cash/Debt

RNTX$9M

RNXT$9M

Current Ratio (TTM)

RNTX4.27x

RNXT5.74x

Quick Ratio (TTM)

RNTX4.26x

RNXT5.37x

Debt/Equity (TTM)

RNTX0.00x

RNXT0.00x

Debt/Assets (TTM)

RNTX0.0%

RNXT0.0%

Interest Coverage (TTM)

RNTXN/A

RNXTN/A

Net Debt/EBITDA (TTM)

RNTX0.00x

RNXT0.00x

Beta

RNTX1.40

RNXT1.07

52W Performance

RNTX-42.9%

RNXT5.8%

YTD Performance

RNTX-36.5%

RNXT53.3%

% from 52W High

RNTX-63.6%

RNXT-50.6%

% from 52W Low

RNTX14.4%

RNXT82.7%

Asset Turnover (TTM)

RNTX0.00x

RNXT0.18x

FCF Yield (TTM)

RNTX-27.7%

RNXT-20.7%

Earnings Yield (TTM)

RNTX-73.3%

RNXT-21.3%

Dividend Yield (TTM)

RNTXN/A

RNXTN/A

Rule of 40

RNTX0.0

RNXT-405.6

EV/GP/RG

RNTXN/A

RNXT0.12

Ticker research

View RNTX research View RNXT research

Metric	RNTX Rein Therapeutics Inc	RNXT RenovoRx Inc
Market & Valuation
Market Cap	$68M	$58M
Enterprise Value	$59M	$48M
Price	$0.79	$1.28
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	29.18x
EV/Sales	0.00x	24.39x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.25x	7.94x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.15x	-4.04x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	8.70x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	198.5%
Forward Rev Growth	113.7%	195.2%
Profitability
Gross Margin (TTM)	0.0%	84.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-684.9%
Net Margin (TTM)	0.0%	-621.7%
FCF Margin (TTM)	N/A	-604.1%
Net Income (TTM)	$-50M	$-12M
FCF (TTM)	$-19M	$-12M
EPS (TTM)	-$0.74	-$0.26
ROE (TTM)	-15323.0%	-14563.0%
ROA (TTM)	-11700.0%	-10984.0%
ROIC (TTM)	-14763.0%	-14563.0%
Financial Health
Cash	$9M	$9M
Debt	$0	$0
Net Cash/Debt	$9M	$9M
Current Ratio (TTM)	4.27x	5.74x
Quick Ratio (TTM)	4.26x	5.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	1.07
52W Performance	-42.9%	5.8%
YTD Performance	-36.5%	53.3%
% from 52W High	-63.6%	-50.6%
% from 52W Low	14.4%	82.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-27.7%	-20.7%
Earnings Yield (TTM)	-73.3%	-21.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-405.6
EV/GP/RG	N/A	0.12
Ticker research	View RNTX research	View RNXT research

Valuation

P/S Ratio

RNTX

0.00x

RNXT

29.18x

EV/FCF

RNXT

-4.04x

RNTX

-3.15x

Growth & revenue

Revenue Growth TTM

RNXT

198.5%

Forward Revenue Growth

RNXT

195.2%

RNTX

113.7%

Profitability & performance

Gross Margin

RNXT

84.4%

RNTX

0.0%

ROE

RNXT

-14563.0%

RNTX

-15323.0%

FCF Yield %

RNXT

-20.7%

RNTX

-27.7%

52-Week Performance

RNXT

5.8%

RNTX

-42.9%

Detailed metrics comparison

RNTX

Rein Therapeutics Inc

RNXT

RenovoRx Inc

Market Cap

RNTX$68M

RNXT$58M

Enterprise Value

RNTX$59M

RNXT$48M

Price

RNTX$0.79

RNXT$1.28

P/E Ratio

RNTXN/A

RNXTN/A

P/S Ratio

RNTX0.00x

RNXT29.18x

EV/Sales

RNTX0.00x

RNXT24.39x

EV/EBITDA

RNTX0.00x

RNXT0.00x

P/B Ratio

RNTX1.25x

RNXT7.94x

P/FCF Ratio

RNTXN/A

RNXTN/A

EV/FCF

RNTX-3.15x

RNXT-4.04x

PEG Ratio

RNTXN/A

RNXTN/A

Forward P/E (NTM)

RNTXN/A

RNXTN/A

Forward P/S (NTM)

RNTXN/A

RNXT8.70x

Revenue (TTM)

RNTX$0

RNXT$2M

Revenue Growth (YoY)

RNTXN/A

RNXT198.5%

Forward Rev Growth

RNTX113.7%

RNXT195.2%

Gross Margin (TTM)

RNTX0.0%

RNXT84.4%

Operating Margin (TTM)

RNTX0.0%

RNXT0.0%

EBITDA Margin (TTM)

RNTX0.0%

RNXT-684.9%

Net Margin (TTM)

RNTX0.0%

RNXT-621.7%

FCF Margin (TTM)

RNTXN/A

RNXT-604.1%

Net Income (TTM)

RNTX$-50M

RNXT$-12M

FCF (TTM)

RNTX$-19M

RNXT$-12M

EPS (TTM)

RNTX-$0.74

RNXT-$0.26

ROE (TTM)

RNTX-15323.0%

RNXT-14563.0%

ROA (TTM)

RNTX-11700.0%

RNXT-10984.0%

ROIC (TTM)

RNTX-14763.0%

RNXT-14563.0%

Cash

RNTX$9M

RNXT$9M

Debt

RNTX$0

RNXT$0

Net Cash/Debt

RNTX$9M

RNXT$9M

Current Ratio (TTM)

RNTX4.27x

RNXT5.74x

Quick Ratio (TTM)

RNTX4.26x

RNXT5.37x

Debt/Equity (TTM)

RNTX0.00x

RNXT0.00x

Debt/Assets (TTM)

RNTX0.0%

RNXT0.0%

Interest Coverage (TTM)

RNTXN/A

RNXTN/A

Net Debt/EBITDA (TTM)

RNTX0.00x

RNXT0.00x

Beta

RNTX1.40

RNXT1.07

52W Performance

RNTX-42.9%

RNXT5.8%

YTD Performance

RNTX-36.5%

RNXT53.3%

% from 52W High

RNTX-63.6%

RNXT-50.6%

% from 52W Low

RNTX14.4%

RNXT82.7%

Asset Turnover (TTM)

RNTX0.00x

RNXT0.18x

FCF Yield (TTM)

RNTX-27.7%

RNXT-20.7%

Earnings Yield (TTM)

RNTX-73.3%

RNXT-21.3%

Dividend Yield (TTM)

RNTXN/A

RNXTN/A

Rule of 40

RNTX0.0

RNXT-405.6

EV/GP/RG

RNTXN/A

RNXT0.12

Ticker research

View RNTX research View RNXT research

Metric	RNTX Rein Therapeutics Inc	RNXT RenovoRx Inc
Market & Valuation
Market Cap	$68M	$58M
Enterprise Value	$59M	$48M
Price	$0.79	$1.28
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	29.18x
EV/Sales	0.00x	24.39x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.25x	7.94x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.15x	-4.04x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	8.70x
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	198.5%
Forward Rev Growth	113.7%	195.2%
Profitability
Gross Margin (TTM)	0.0%	84.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-684.9%
Net Margin (TTM)	0.0%	-621.7%
FCF Margin (TTM)	N/A	-604.1%
Net Income (TTM)	$-50M	$-12M
FCF (TTM)	$-19M	$-12M
EPS (TTM)	-$0.74	-$0.26
ROE (TTM)	-15323.0%	-14563.0%
ROA (TTM)	-11700.0%	-10984.0%
ROIC (TTM)	-14763.0%	-14563.0%
Financial Health
Cash	$9M	$9M
Debt	$0	$0
Net Cash/Debt	$9M	$9M
Current Ratio (TTM)	4.27x	5.74x
Quick Ratio (TTM)	4.26x	5.37x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	1.07
52W Performance	-42.9%	5.8%
YTD Performance	-36.5%	53.3%
% from 52W High	-63.6%	-50.6%
% from 52W Low	14.4%	82.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-27.7%	-20.7%
Earnings Yield (TTM)	-73.3%	-21.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-405.6
EV/GP/RG	N/A	0.12
Ticker research	View RNTX research	View RNXT research